Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.56 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24962981 | 0.90 | GPR119 (0.59) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL28966566 | 0.90 | GPR119 (0.59) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL24963667 | 0.90 | GPR119 (0.59) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL12089264 | 0.89 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL31713163 | 0.89 | GPR119 (0.60) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL16154 | 0.86 | SLC6A7 (0.43) | GPR119KCNH2 | |
| SCHEMBL1449149 | 0.84 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL1449147 | 0.84 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1KCNH2 | |
| SCHEMBL22792019 | 0.84 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL12740838 | 0.84 | GPR119 (0.65) | GPR119SMARCA2SMARCA4PBRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GPR119 17/4885SMARCA2 4060/4885SMARCA4 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.